Bioequivalence and Bioavailability Forum 04:21 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

calculation of 90% CI for continuous variable in clinical endpoint studies [General Sta­tis­tics]

posted by GM - India, 2017-11-17 04:55  - Posting: # 17986
Views: 2,693

(edited by GM on 2017-11-17 05:07)

Hello All,

As I am new to the endpoint studies, how can we calculate 90% CI for continuous variable in clinical endpoint studies?

As per my understanding, there are two ways. One is ±20 rule for the difference of means and 80-120% rule for ratio of means of un-transformed data. Based on this reference 90% CI Calculation

But as per OGD, the 90%CI should lies in 80-125% for un-transformed data. Please see the point no.21 in the OGD (see Clindamycin Phosphate).

This is :confused: me a lot. Please clarify.


Edit: URL corrected. Please don’t link to a Google-India search term. [Helmut]

Best Regards,
GM

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,939 posts in 4,040 threads, 1,288 registered users;
online 11 (0 registered, 11 guests [including 6 identified bots]).

Outside his own ever-narrowing field of specialization,
a scientist is a layman.
What members of an academy of science have in common
is a certain form of semiparasitic living.    Erwin Chargaff

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed